| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Comirnaty | |
| 3 | Economics | BioNTech 50% gross profit split | |
| 4 | MOA | mRNA vaccine | |
| 5 | Regulatory | 6/2022: EUA for 3-3ug dose series for 6mo-4yo | |
| 6 | 5/2022: EUA granted for 5-11yo booster dose (10ug 5 months after 2nd 10ug dose) | ||
| 7 | Clinical Trials | ||
| 8 | Phase II/III third 3ug dose in children 6 months to 5 years | ||
| 9 | |||
| 10 | |||
| 11 | Phase III vs current | ||
| 12 | Monovalent Omicron 30ug, 60ug | ||
| 13 | NaN/NaN/NaN | ||
| 14 | Bivalent Omicron BA.1+current | ||
| 15 | 9.1x and 10.9x | ||
| 16 | |||
| 17 | BNT162b5: Enhanced mRNA-based vaccine 30ug | ||
| 18 | wild-type and Omicron, enhanced spike protein |